Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0113 in CMV-seronegative Kidney Transplant Recipients
NCT01974206Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2013
- Primary completion
- May 2016
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 6
01
Overview
A Phase 2 trial of ASP0113 in cytomegalovirus infection (CMV), sponsored by Astellas Pharma. Started Nov 2013; status: completed.
02
Drugs
ASP0113
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT01974206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01974206.